DANA-FARBER CANCER INST
Protein O' Mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma
Protein O' Mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma is a funding opportunity from DANA-FARBER CANCER INST, up to 721653, closing May 31, 2031.
May 31, 2031
(1765d left)Overview
Abstract Pediatric low-grade gliomas (pLGGs) are the most frequent solid tumor of childhood and include Pilocytic Astrocytomas (PAs). Approximately 75% of PAs result from a single driver event: a rearrangement between BRAF and the uncharacterized protein KIAA1549. The KIAA1549-BRAF fusion protein drives glioma…